Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPEAT: Natpara in Hypoparathyroidism
NCT01455181Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2011
- Primary completion
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of parathyroid hormone 1-84 in hypoparathyroidism, sponsored by Takeda. Primary endpoint: Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24. Started Aug 2011; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT01455181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01455181.